lyophilisation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
In ancient times, one highly abrasive depilatory paste consisted of an admixture of slaked lime, water, wood-ash and yellow orpiment (arsenic trisulfide); In rural India and Iran, where this mixture is called vajibt, it is still commonly used to remove pubic hair. In other cultures, oil extracted from unripe olives (which had not reached one-third of their natural stage of ripeness) was used to remove body hair. During the medieval period, Catholic women were expected to let their hair grow long as a display of femininity, whilst keeping the hair concealed by wearing a wimple headdress in public places. The face was the only area where hair growth was considered unsightly; 14th-century ladies would also pick off hair from their foreheads to recede the hairline and give their face a more oval form. From the mid-16th century, it is said when Queen Elizabeth I came to power, she made eyebrow removal fashionable. By the 18th century, body hair removal was still considered a non-necessity by European and American women. But in 1760, when the first safety straight razor appeared for men to safely shave their beard and not inadvertently cut themselves, some women allegedly used this safety razor too. It was invented in Paris by the French master cutler Jean-Jacques Perret, author of La pogonotomie, ou L'art d'apprendre à se raser soi-même (Pogonotomy, or The Art of Learning to Shave). It was not until the late 19th century that women in Europe and America started to make hair removal a component of their personal care regime.
=== DHIS 1.3 and 1.4 === The DHIS version 1 series goes back to 1996 and was developed on the Microsoft Access platform consisting of VBA for the interface or program logic (front-end), Access as a database (back-end), Excel for reporting and Windows as the OS. DHIS 1.4 (from 2005) is a significant overhaul of the version 1.3 database structure, using various output formats for reporting. It bridges the gap between DHIS 1.3 and 2.
She said the Daxor donor of the sperm that she used had lied significantly about his education, and had failed to disclose that he was diagnosed with ADHD, did not speak until age 3, and attended a special school for children with learning and emotional disabilities; she said using his sperm led to both of her children being diagnosed with autism.
===== MeSH D08.811.682.047 – alcohol oxidoreductases ===== MeSH D08.811.682.047.050 – acetoin dehydrogenase MeSH D08.811.682.047.070 – alcohol dehydrogenase MeSH D08.811.682.047.150 – carbohydrate dehydrogenases MeSH D08.811.682.047.150.225 – fructuronate reductase MeSH D08.811.682.047.150.250 – galactose dehydrogenases MeSH D08.811.682.047.150.270 – glucose dehydrogenases MeSH D08.811.682.047.150.270.500 – glucose 1-dehydrogenase MeSH D08.811.682.047.150.300 – glucosephosphate dehydrogenase MeSH D08.811.682.047.150.600 – phosphogluconate dehydrogenase MeSH D08.811.682.047.150.650 – phosphoglycerate dehydrogenase MeSH D08.811.682.047.150.700 – sugar alcohol dehydrogenases MeSH D08.811.682.047.150.700.075 – aldehyde reductase MeSH D08.811.682.047.150.700.237 – d-xylulose reductase MeSH D08.811.682.047.150.700.400 – glycerolphosphate dehydrogenase MeSH D08.811.682.047.150.700.400.500 – glycerol-3-phosphate dehydrogenase (nad+) MeSH D08.811.682.047.150.700.437 – l-gulonolactone oxidase MeSH D08.811.682.047.150.700.475 – l-iditol 2-dehydrogenase MeSH D08.811.682.047.150.700.649 – mannitol dehydrogenase MeSH D08.811.682.047.150.900 – uridine diphosphate glucose dehydrogenase MeSH D08.811.682.047.180 – choline dehydrogenase MeSH D08.811.682.047.210 – galactose oxidase MeSH D08.811.682.047.239 – glucose oxidase MeSH D08.811.682.047.370 – homoserine dehydrogenase MeSH D08.811.682.047.370.060 – aspartokinase homoserine dehydrogenase MeSH D08.811.682.047.385 – 3-hydroxyacyl coa dehydrogenases MeSH D08.811.682.047.385.415 – hydroxymethylglutaryl coa reductases MeSH D08.811.682.047.385.415.250 – hydroxymethylglutaryl-coa reductases, nad-dependent MeSH D08.811.682.047.385.415.750 – hydroxymethylglutaryl-coa-reductases, nadp-dependent MeSH D08.811.682.047.393 – hydroxybutyrate dehydrogenase MeSH D08.811.682.047.428 – Hydroxyprostaglandin dehydrogenase MeSH D08.811.682.047.432 – hydroxypyruvate reductase MeSH D08.811.682.047.436 – hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.174 – 11-beta-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.174.300 – 11-beta-hydroxysteroid dehydrogenase type 1 MeSH D08.811.682.047.436.174.600 – 11-beta-hydroxysteroid dehydrogenase type 2 MeSH D08.811.682.047.436.350 – 3-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.350.100 – 3alpha-hydroxysteroid dehydrogenase (B-specific) MeSH D08.811.682.047.436.350.150 – cholesterol oxidase MeSH D08.811.682.047.436.350.700 – progesterone reductase MeSH D08.811.682.047.436.375 – 17-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.375.280 – estradiol dehydrogenases MeSH D08.811.682.047.436.400 – 20-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.400.074 – 20alpha-hydroxysteroid dehydrogenase MeSH D08.811.682.047.436.400.150 – cortisone reductase MeSH D08.811.682.047.485 – imp dehydrogenase MeSH D08.811.682.047.497 – isocitrate dehydrogenase MeSH D08.811.682.047.500 – 3-isopropylmalate dehydrogenase MeSH D08.811.682.047.524 – ketol-acid reductoisomerase MeSH D08.811.682.047.551 – lactate dehydrogenases MeSH D08.811.682.047.551.249 – epsilon-crystallins MeSH D08.811.682.047.551.400 – l-lactate dehydrogenase MeSH D08.811.682.047.551.500 – l-lactate dehydrogenase (cytochrome) MeSH D08.811.682.047.605 – malate dehydrogenase MeSH D08.811.682.047.748 – malate dehydrogenase (nadp+) MeSH D08.811.682.047.892 – xanthine dehydrogenase MeSH D08.811.682.047.928 – xanthine oxidase
Sources: en.wikipedia.org
== Human studies == Meso-zeaxanthin is a regular dietary component in countries where it is a major pigment used by the poultry industry, particularly in Mexico. Neither adverse nor positive effects have yet been reported. In addition, meso-zeaxanthin has been tested for efficacy, though not for safety, in small pilot studies in humans. The first study to evaluate the effects of a dietary supplement containing predominantly meso-zeaxanthin was conducted in 2007. This research confirmed that meso-zeaxanthin was effectively absorbed into the serum, and MP density was increased significantly in the supplementation group. No such increases were observed in the placebo group. In another study 19 subjects consumed a supplement composed of all three macular carotenoids, including meso-zeaxanthin, for 22 days. Results demonstrated that meso-zeaxanthin was absorbed. At the Institute of Vision Research, Waterford Institute of Technology, the Meso-zeaxanthin Ocular Supplementation Trials (MOST), have been conducted to evaluate safety, MP response, and serum carotenoid response in subjects with and without AMD, following consumption of a supplement containing all three macular carotenoids in which meso-zeaxanthin was predominant. These studies confirmed safety for human consumption of the macular carotenoids following many biological tests to assess renal and liver functions, lipid profile, hematologic profile, and markers of inflammation. Also, the MOST trials identified statistically significant increases in serum concentrations of meso-zeaxanthin and lutein from baseline.
== Material processing == For most manufacturing applications, specific material requirements must be satisfied. Mineral ores need to be refined to extract specific metals, and volatile organic compounds will need to be purified. Ideally these raw materials are delivered to the processing site in an economical manner, where time to arrival, propulsion energy expenditure, and extraction costs are factored into the planning process. Minerals can be obtained from asteroids, the lunar surface, or a planetary body. Volatiles could potentially be obtained from a comet, carbonaceous chondrite or "C-Type" asteroids, or the moons of Mars or other planets. It may also prove possible to extract hydrogen in the form of water ice or hydrated minerals from cold traps on the poles of the Moon. Unless the materials processing and the manufacturing sites are co-located with the resource extraction facilities, the raw materials would need to be moved about the Solar System. There are several proposed means of providing propulsion for this material, including solar sails, electric sails, magnetic sails, electric ion thrusters, microwave electrothermal thrusters, or mass drivers (this last method uses a sequence of electromagnets mounted in a line to accelerate a conducting material). At the materials processing facility, the incoming materials will need to be captured by some means. Maneuvering rockets attached to the load can park the content in a matching orbit.
It included industrial workers and smallholders, broad middle class (including both the agrarian and urban middle classes), as well as entrepreneurs, civil servants and clerics, and lastly a small but influential group of Catholic aristocracy. The uniting element of the factions of the Centre Party was commitment to Political Catholicism. The party also urged union with Austria. The party had a left wing, represented by politicians such as Constantin Fehrenbach, Matthias Erzberger, Joseph Wirth, as well as Catholic workers' associations and trade unions, led by the Centre's laborist politicians such as Adam Stegerwald. Left-wing factions of the Centre Party were committed to republicanism and pressured the Zentrum to officially identify itself as a pro-republican party; however, the party instead adopted a vague label of being a "constitutional party", which was "ready to collaborate with any legal government". The leftists of the Centre Party also promoted cooperation with the SPD and advised Weimar Catholics to join the Reichsbanner; some left-wing Centre factions were also supportive of cooperation with right-wing nationalist trade unions on pragmatic basis. Along with "republican-democratic" wings of the party, the Centre Party also had socialist factions.
S. haemolyticus can colonize central venous catheters and cause serious medical complications. Colonization occurs when S. haemolyticus migrates from the skin, along the external surface of the device, or from the hub, due to manipulation by health care workers. In either scenario, a high probability exists that the microbe will form a biofilm. These infections can remain localized or become systemic (i.e. bacteremia). The severity of infection varies depending on the type of catheter, frequency of manipulation, and virulence factors of the S. haemolyticus strain. Removal of the catheter is usually considered to be the best treatment, but this is not always possible. Alternatively, vancomycin or teicoplanin may be administered. Recent evidence suggests that glycopeptides can be supplemented with β-lactams to work synergistically.
== Recombinant chymosin == Because of the imperfections and scarcity of microbial and animal rennets, producers sought replacements. With the development of genetic engineering, it became possible to extract rennet-producing genes from animal stomach and insert them into certain bacteria, fungi or yeasts to make them produce chymosin during fermentation. The genetically modified microorganism is killed after fermentation and chymosin is isolated from the fermentation broth, so that the fermentation-produced chymosin (FPC) used by cheese producers does not contain any GM component or ingredient. FPC contains the identical chymosin as the animal source, but produced in a more efficient way. FPC products have been on the market since 1990 and are considered the ideal milk-clotting enzyme. FPC was the first artificially produced enzyme to be registered and allowed by the US Food and Drug Administration. In 1999, about 60% of US hard cheese was made with FPC and it has up to 80% of the global market share for rennet. By 2008, approximately 80% to 90% of commercially made cheeses in the US and Britain were made using FPC. The most widely used fermentation-produced chymosin is produced either using the fungus Aspergillus niger or using Kluyveromyces lactis. FPC contains only chymosin B, achieving a higher degree of purity compared with animal rennet. FPC can deliver several benefits to the cheese producer compared with animal or microbial rennet, such as higher production yield, better curd texture and reduced bitterness.
Sources: en.wikipedia.org
=== Honors and awards === On December 4, 2015, Sanders won Time's 2015 Person of the Year readers' poll with 10.2% of the vote but did not receive the editorial board's award. On March 20, 2016, he was given an honorary Lushootseed name, dxʷshudičup, by Deborah Parker in Seattle to honor his focus on Native American issues during his presidential campaign. On May 30, 2017, Sanders received an honorary degree of Doctor of Humane Letters from Brooklyn College.
== Awards and honors == 2018 Elected fellow of the American Academy of Microbiology 2020 American Society for Microbiology Award for Research and Leadership in Clinical Microbiology Academy of Clinical Laboratory Physicians and Scientists Ellis S. Benson Award "40 Under 40" honoree by the American Society for Clinical Pathology
Rotaxane-based molecular machines have been of initial interest for their potential use in molecular electronics as logic molecular switching elements and as molecular shuttles. These molecular machines are usually based on the movement of the macrocycle on the dumbbell. The macrocycle can rotate around the axis of the dumbbell like a wheel and axle or it can slide along its axis from one site to another. Controlling the position of the macrocycle allows the rotaxane to function as a molecular switch, with each possible location of the macrocycle corresponding to a different state. These rotaxane machines can be manipulated both by chemical and photochemical inputs. Rotaxane based systems have also been shown to function as molecular muscles. In 2009, there was a report of a "domino effect" from one extremity to the other in a Glycorotaxane Molecular Machine. In this case, the 4C1 or 1C4 chair-like conformation of the mannopyranoside stopper can be controlled, depending on the localization of the macrocycle. In 2012, unique pseudo-macrocycles consisting of double-lasso molecular machines (also called rotamacrocycles) were reported in Chem. Sci. These structures can be tightened or loosened depending on pH. A controllable jump rope movement was also observed in these new molecular machines.
People sometimes think that I and the others worked on penicillin because we were interested in suffering humanity. I don't think it ever crossed our minds about suffering humanity. This was an interesting scientific exercise, and because it was of some use in medicine is very gratifying, but this was not the reason that we started working on it. Florey approached the MRC for funding in September 1939, shortly after the outbreak of the Second World War, and Mellanby authorised the project, allocating £250 (equivalent to £14,128 in 2025) to launch the project, with £300 for salaries and £100 for expenses per annum for three years. Florey felt that more would be required. On 1 November 1939, Henry M. "Dusty" Miller, Jr, from the Natural Sciences Division of the Rockefeller Foundation dropped by to discuss funding Heatley's position. Heatley had fallen out with Chain, and had accepted a new position at the Carlsberg Laboratory in Copenhagen on a Rockefeller Fellowship, but due to the outbreak of the Second World War, he had decided to remain at Oxford. Miller arranged for Heatley to retain his fellowship. Instead of working for Chain, Heatley would report directly to Florey as his personal research assistant.
CHO cells are the most common mammalian cell line used for mass production of therapeutic proteins such as monoclonal antibodies, used in 70% of therapeutic mAbs. They can produce recombinant protein on the scale of 3–10 grams per liter of culture. Products of CHO cells are suitable for human applications, as these mammalian cells perform human-like post-translational modifications to recombinant proteins, which is key to the functioning of several proteins. It is believed that CHO-K1 transgenic cells are characterized by higher monoclonal antibody expression at the expense of biomass accumulation, for example, based on CHO-K1, monoclonal antibody‑producing cell lines with productivity up to 6.5 grams per liter have been selected. Cell culture Drug development Preclinical development
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.